

Timothy C Hardman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3074161/publications.pdf>

Version: 2024-02-01

62
papers

1,000
citations

516561

16
h-index

454834

30
g-index

65
all docs

65
docs citations

65
times ranked

1352
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 721-733. | 2.9 | 98 |
| 2 | Composite type-2 biomarker strategy versus a symptomâ€‘risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 57-68. | 5.2 | 88 |
| 3 | Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). <i>Thorax</i> , 2016, 71, 187-189. | 2.7 | 78 |
| 4 | An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes - the MID-Frail study: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 34. | 0.7 | 65 |
| 5 | New lipid-lowering drugs: an update. <i>International Journal of Clinical Practice</i> , 2012, 66, 270-280. | 0.8 | 61 |
| 6 | Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 887-898. | 1.0 | 52 |
| 7 | Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. <i>Diabetes Therapy</i> , 2011, 2, 133-145. | 1.2 | 52 |
| 8 | Sarcoidosis: the links between epidemiology and aetiology. <i>Postgraduate Medical Journal</i> , 2014, 90, 582-589. | 0.9 | 51 |
| 9 | Future Challenges for Microsomal Transport Protein Inhibitors. <i>Current Vascular Pharmacology</i> , 2009, 7, 277-286. | 0.8 | 43 |
| 10 | Controversies surrounding erythrocyte sodium-lithium countertransport. <i>Journal of Hypertension</i> , 1996, 14, 695-703. | 0.3 | 37 |
| 11 | HIV lipodystrophy and its metabolic consequences: implications for clinical practice. <i>Current Medical Research and Opinion</i> , 2008, 24, 609-624. | 0.9 | 36 |
| 12 | Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 667-676. | 1.9 | 36 |
| 13 | A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. <i>GeroScience</i> , 2021, 43, 1317-1329. | 2.1 | 31 |
| 14 | A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. <i>Trials</i> , 2018, 19, 5. | 0.7 | 26 |
| 15 | New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457. | 0.8 | 22 |
| 16 | Erythrocyte sodium-lithium countertransport and blood pressure in identical twin pairs discordant for insulin dependent diabetes.. <i>BMJ: British Medical Journal</i> , 1992, 305, 215-219. | 2.4 | 21 |
| 17 | Transport of phytanic acid on lipoproteins in Refsum disease. <i>Journal of Inherited Metabolic Disease</i> , 1999, 22, 29-36. | 1.7 | 17 |
| 18 | Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’. <i>Current Pharmaceutical Design</i> , 2010, 16, 3830-3838. | 0.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Exacerbation Profile and Risk Factors in a Type-2â€“Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553. | 2.5 | 14 |
| 20 | Sodium-lithium countertransport activity is not affected by short-term insulin exposure in vivo or in a physiologic medium in vitro. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1087-1089. | 1.5 | 11 |
| 21 | Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in black normotensive subjects compared with three other ethnic groups. <i>Journal of Human Hypertension</i> , 1998, 12, 29-34. | 1.0 | 10 |
| 22 | The apolipoprotein E2 allele modulates activity and maximal velocity of the sodiumâ€“lithium countertransporter1. <i>American Journal of Hypertension</i> , 2002, 15, 633-637. | 1.0 | 10 |
| 23 | Ready! Aim! Fire! targeting the right medical science journal. <i>Cardiovascular Endocrinology</i> , 2017, 6, 95-100. | 0.8 | 10 |
| 24 | Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery disease. <i>American Journal of Hypertension</i> , 1996, 9, 184-187. | 1.0 | 9 |
| 25 | Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor. <i>European Journal of Clinical Pharmacology</i> , 2001, 56, 805-811. | 0.8 | 9 |
| 26 | Action of Dipeptidyl Peptidaseâ€“4 Inhibitors on SARSâ€“CoVâ€“2 Main Protease. <i>ChemMedChem</i> , 2021, 16, 1425-1426. | 1.6 | 9 |
| 27 | Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768. | 3.1 | 8 |
| 28 | Relation between sodiumâ€“lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. <i>American Journal of Hypertension</i> , 2001, 14, 32-37. | 1.0 | 7 |
| 29 | Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma. <i>Pathology</i> , 2020, 52, 538-545. | 0.3 | 7 |
| 30 | Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376. | 2.7 | 7 |
| 31 | Erythrocyte Sodium-Lithium Countertransport Activity in Non-Nephropathic Diabetic Twins. <i>Diabetes Care</i> , 1996, 19, 32-38. | 4.3 | 5 |
| 32 | Characterization of the Erythrocyte Sodium-Lithium Countertransporter: Limitations and Assumptions of Traditional and Kinetic Methodologies. <i>Journal of Membrane Biology</i> , 1998, 161, 197-205. | 1.0 | 5 |
| 33 | The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum. <i>Frontiers in Pharmacology</i> , 2019, 10, 398. | 1.6 | 5 |
| 34 | Kinetic behavior of the erythrocyte sodium-lithium countertransporter in nonnephropathic diabetic twins. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1203-1207. | 1.5 | 4 |
| 35 | Review: Clinical aspects of the management of HIV lipodystrophy. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 113-119. | 0.6 | 4 |
| 36 | Bariatric surgery in obese older people. <i>Cardiovascular Endocrinology</i> , 2015, 4, 60-66. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Ten tips for promoting your research. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 30-35. | 0.5 | 3 |
| 38 | The effect of azoximer bromide (Polyoxidonium [®]) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. <i>Drugs in Context</i> , 2021, 10, 1-10. | 1.0 | 3 |
| 39 | The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges. <i>Frontiers in Pharmacology</i> , 2020, 11, 580560. | 1.6 | 3 |
| 40 | Enoximone in Chronic Stable Angina: A Double-Blind Placebo-Controlled Cross-Over Trial. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 532-538. | 0.8 | 2 |
| 41 | Sodium-lithium countertransport and sodium-hydrogen exchange: the dual modality hypothesis Reply. <i>Journal of Hypertension</i> , 1996, 14, 1153-1154. | 0.3 | 2 |
| 42 | Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. <i>European Journal of Clinical Investigation</i> , 1998, 28, 334-338. | 1.7 | 2 |
| 43 | The current status of antihypertensive treatments: into the new millennium. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 731-737. | 0.9 | 2 |
| 44 | Erythrocyte sodium-lithium countertransport in African American women. <i>Journal of Human Hypertension</i> , 2001, 15, 505-506. | 1.0 | 2 |
| 45 | Correction for the adverse influence of sodium ⁺ potassium cotransport on apparent sodium ⁺ lithium countertransport activity in human erythrocytes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2002, 47, 19-24. | 0.3 | 2 |
| 46 | New therapies in the management of type 2 diabetes mellitus. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 202-207. | 0.2 | 2 |
| 47 | The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development. <i>Frontiers in Pharmacology</i> , 2018, 9, 1301. | 1.6 | 2 |
| 48 | EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management. <i>Frontiers in Pharmacology</i> , 2017, 8, 901. | 1.6 | 2 |
| 49 | How to Interpret an Investigator [™] s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 612-618. | 0.8 | 2 |
| 50 | Short papers in pharmaceutical analysis. <i>Analytical Proceedings</i> , 1993, 30, 361. | 0.4 | 1 |
| 51 | Exercise electrocardiography and aortic Doppler velocimetry in asymptomatic identical twins discordant for type 1 (insulin dependent) diabetes.. <i>Heart</i> , 1994, 71, 341-348. | 1.2 | 1 |
| 52 | Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. <i>Journal of Human Hypertension</i> , 2000, 14, 561-565. | 1.0 | 1 |
| 53 | Pharmacokinetics and Tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1098-1105. | 1.0 | 1 |
| 54 | European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development [™] Be Prepared. <i>Frontiers in Pharmacology</i> , 2019, 10, 1377. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | F012 Triglycerides not insulin resistance principally determine sodium-lithium countertransport activity in patients with familial hyperchylomicronaemia. American Journal of Hypertension, 1998, 11, 156A. | 1.0 | 0 |
| 56 | Cation transport in Bartter's syndrome. Journal of Hypertension, 1998, 16, 549-551. | 0.3 | 0 |
| 57 | Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. Journal of Human Hypertension, 1999, 13, 871-873. | 1.0 | 0 |
| 58 | Na,Li-countertransport and ethnicity. American Journal of Hypertension, 1999, 12, 433-434. | 1.0 | 0 |
| 59 | Drugs in development for the management of dyslipidaemia. Future Prescriber, 2012, 13, 12-15. | 0.1 | 0 |
| 60 | Sodium-Lithium Countertransport Activity Is Linked to Chromosome 5 in Baboons. Hypertension, 2001, 38, . | 1.3 | 0 |
| 61 | Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.. F1000Research, 0, 11, 259. | 0.8 | 0 |
| 62 | Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19. Drugs in Context, 2022, 11, 1-15. | 1.0 | 0 |